American Regent, Inc. Expands Promotional Campaign For Iron Deficiency Anemia Drug Injectafer® (Ferric Carboxymaltose Injection)
SHIRLEY, N.Y.--(BUSINESS WIRE)--American Regent, Inc., a subsidiary of Luitpold Pharmaceuticals, Inc. (a Daiichi Sankyo Group Company), announced today an expanded promotional campaign for Injectafer® (ferric carboxymaltose injection) in the United States. It is also announcing that Injectafer® has received a C code (C9441), which will allow health care providers to be reimbursed for administering Injectafer® to Medicare patients in the outpatient hospital setting. Injectafer® is the first high-dose, non-dextran intravenous (IV) iron for the treatment of adult patients with iron deficiency anemia (IDA) of various etiologies who have intolerance to oral iron or who have had an unsatisfactory response to oral iron. It is also indicated for treatment of IDA in adult patients who have non-dialysis dependent chronic kidney disease. With the US launch of Injectafer®, ferric carboxymaltose (the active ingredient) is now approved in more than 50 countries.
Help employers find you! Check out all the jobs and post your resume.